Reviva Pharmaceuticals Holdings Inc（RVPH）资讯与事件RVPHReviva Pharmaceuticals Holdings Inc

Reviva CEO Reveals brilaroxazine Development Strategy

"During the first quarter, we further refined our development strategy to strengthen the long-term value of brilaroxazine," said Laxminarayan Bhat, Founder, President, and CEO of Reviva. "A key priority is to incorporate a new form of brilaroxazine into our clinical and regulatory pathway, which we believe has the potential to extend patent protection and commercial exclusivity of the program. We expect U.S. Food and Drug Administration feedback on this strategy in mid-2026. In parallel, we are preparing to initiate RECOVER-2, our registrational Phase 3 trial in schizophrenia, with patient enrollment expected to begin in the third quarter of 2026. With multiple milestones ahead in 2026, we are committed to disciplined execution as we advance brilaroxazine as a differentiated treatment option for patients with schizophrenia and other neuropsychiatric disorders."

Reviva Pharmaceuticals Plans Public Offering of Stock and Warrants

Reviva Pharmaceuticals Holdings announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The company currently intends to use the net proceeds from the offering together with its existing cash and cash equivalents to fund research and development activities, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

Reviva Pharmaceuticals Announces 1-for-20 Reverse Stock Split Effective March 9, 2026

In a regulatory filing, Reviva Pharmaceuticals announced that on March 4, the company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which will effect, at 12:01 a.m. Eastern Time on March 9, 2026, a one-for-twenty reverse stock split of the company's issued and outstanding shares of common stock, par value $0.0001 per share. The trading symbol for the Common Stock will remain "RVPH". The company anticipates that the Common Stock will begin trading on a Reverse Stock Split-adjusted basis when the market opens on March 9, 2026. As a result of the Reverse Stock Split, every twenty shares of Common Stock issued and outstanding will be converted into one share of Common Stock. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the company's equity, except to the extent that the Reverse Stock Split would result in some stockholders owning a fractional share. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of Common Stock will automatically be entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share.